Allegion Plc (ALLE) 2Q beat, raising estimates

Research evidence excerpt

Allegion Plc (ALLE) 2Q beat, raising estimates

Goldman Sachs Allegion Plc (ALLE)

policy constraints due to Goldman Sachs’ involvement in a transaction, and in certain other circumstances. Early-Stage Biotech (ES). An investment

rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that

has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. Rating Suspended (RS). Goldman Sachs

Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an

investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied

upon. Coverage Suspended (CS). Goldman Sachs has suspended coverage of this company. Not Covered (NC). Goldman Sachs does not cover this

company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based

in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities

and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs

do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or

contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil:

0800 727 5764 e/ou contatogoldmanbrasil@gs.com.